Determining prognostic immune markers in patients with ovarian cancer * a prospective explorative cohort study.
Recruiting
- Conditions
- 10038594Ovarian cancer
- Registration Number
- NL-OMON48676
- Lead Sponsor
- eids Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 300
Inclusion Criteria
* Patients with (suspicion of) primary or recurrent EOC with an indication for
surgery, chemotherapy and/or immunotherapy.
* Age *18 years.
* WHO performance status 0-2.
* Accessible for treatment and follow-up.
* Written informed consent.
Exclusion Criteria
* Other active malignancy in past 5 years prior to entry into the study, except
for treated non-melanoma skin cancer.
* Any known severe infection like HIV, hepatitis A, B and C.
* Receiving immune suppressive treatment.
* Medical or psychological condition which in the opinion of the investigator
would not permit the patient to complete the study or sign meaningful informed
consent.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Association between the mMDSC/DC ratio in PBMCs in patients with recurrent EOC<br /><br>before the start of treatment and OS.</p><br>
- Secondary Outcome Measures
Name Time Method